50 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute Of Mit And Harvard
From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
Laboratoires Fournier
Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships ofa,a-tetrahydropyranylglycine.
Menarini Ricerche
Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Cortech
Synopsis of some recent tactical application of bioisosteres in drug design.
Bristol-Myers Squibb Pharmaceutical Research And Development
Discovery of a potent and selective small molecule hGPR91 antagonist.
Advinus Therapeutics
Quinolinyl- and phenantridinyl-acetamides as bradykinin B1 receptor antagonists.
Gedeon Richter
2-Aminobenzophenones as a novel class of bradykinin B1 receptor antagonists.
Merck Research Laboratories
A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity.
Merck Research Laboratories
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.
Merck Research Laboratories
Benzodiazepines as potent and selective bradykinin B1 antagonists.
Merck Research Laboratories
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
University Of Montpellier
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency.
Amgen
Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists.
Amgen
Progress in structure based drug design for G protein-coupled receptors.
Heptares Therapeutics
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.
Amgen
Bradykinin B1 receptor antagonists as potential therapeutic agents for pain.
Johnson & Johnson Pharmaceutical Research And Development
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical And Public Health Institute
Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists.
Amgen
Novel small molecule bradykinin B1 receptor antagonists. Part 3: hydroxyurea derivatives.
Jerini
Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles.
Jerini
Novel small molecule bradykinin B1 receptor antagonists. Part 1: benzamides and semicarbazides.
Jerini
1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B(1) receptor antagonists.
Neurogen
Bradykinin B1 receptor antagonists: an alpha-hydroxy amide with an improved metabolism profile.
Merck
Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic pain.
Amgen
Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists.
Amgen
Novel bradykinin-1 antagonists containing a (1,2,3,4-tetrahydro-isoquinolin-1-yl)acetic acid scaffold.
University Of Szeged
Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists.
Elan Pharmaceuticals
Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series.
Merck
Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Amgen
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.
Amgen
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
Merck Research Laboratories
5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists.
Merck Research Laboratories
Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.
TBA
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
Amgen
2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.
Merck Research Laboratories
Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies.
Merck Research Laboratories
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
TBA
A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.
University Of Montpellier
Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.
University Of Montpellier
